Category: PLC Systems Inc.
PLC Systems reported a revenue surge, which has allowed the company to reduce its losses significantly.
PLC Systems (OTC:PLCSF) is cutting down on its losses, thanks in part to strong revenues during the 3rd quarter.
PLC Systems posted losses of $609,000, or -1¢ per share, on sales of $348,000 for the 3 months ended Sept. 30, narrowing losses by 81% and boosting sales 64.2% over the same period last year.
The Japanese Ministry of Health, Labor & Welfare approves a clinical trial of PLC Systems' RenalGuard device.
PLC Systems (OTC:PLCSF) won approval from the Japanese Ministry of Health, Labor & Welfare for a clinical trial of its RenalGuard device.
Massachusetts-based PLC Systems touts a $1.75 million raise through sales of common stock and 5-year warrants.
Medical device maker PLC Systems (PINK:PLCSF) touted a new $1.75 million raise, which the company plans to use to fund its ongoing U.S. pivotal trial for the RenalGuard system.
PLC Systems treats the 1st patient with its RenalGuard in a trial to evaluate the device in patients with acute kidney failure undergoing heart valve replacement procedures.
PLC Systems (PINK:PLCSF) said its RenalGuard device was used in a new clinical trial evaluating the device in treating patients with acute kidney failure undergoing transcatheter aortic valve implantation.
The FDA approves Johnson & Johnson's 1st-of-a-kind Invokana diabetes drug, designed to flush unabsorbed sugar from the bloodstream.
The FDA approved a 1st-of-its-kind treatment for Type 2 diabetes, Johnson & Johnson's (NYSE:JNJ) Invokana, with the federal watchdog agency citing it as a pioneer in a new class of diabetes drug.